SCM
CNSP icon

Stonepine Capital Management’s CNS Pharmaceuticals CNSP Stock Holding History

Stonepine Capital Management’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Sell
41,573
-19,427
-32% -$81.6K 0.11% 80
2026
Q1 		$146K Buy
61,000
+12,173
+25% +$50.4K 0.06% 75
2025
Q4 		$256K Buy
+48,827
New +$366K 0.19% 59

Other funds holding CNSP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Stonepine Capital Management's CNSP Position: Q2 2026 in Review

Stonepine Capital Management reduced its CNS Pharmaceuticals (CNSP) stake by 32% in Q2 2026, selling an estimated $81.6K and leaving 41,573 shares worth $199K. The position accounts for 0.11% of the portfolio, ranked #80.

Stonepine Capital Management first reported a position in CNSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $256K in Q4 2025. 11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • Stonepine Capital Management held 41,573 shares of CNS Pharmaceuticals worth $199K as of Q2 2026.
  • Stonepine Capital Management sold 19,427 CNS Pharmaceuticals shares in Q2 2026, an estimated $81.6K.
  • CNS Pharmaceuticals made up 0.11% of Stonepine Capital Management's portfolio in Q2 2026, its #80 holding.
  • Stonepine Capital Management first reported a position in CNS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Stonepine Capital Management's CNS Pharmaceuticals position peaked at $256K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.